Product Description
uPath PD-L1 (SP263) image analysis, NSCLC*
The uPath PD-L1 (SP263) image analysis, NSCLC algorithm is an adjunctive computer-assisted tool that identifies PD-L1 positive and negative tumor cells within a pathologist-annotated viable tumor region in images of formalin-fixed, paraffin-embedded Non-small cell lung cancer (NSCLC) tissue.
*CE-IVD marked. For Research Use Only in the US. Not for use in diagnostic procedures in the US.
A robust and reliable solution for enhanced image analysis
Integrated and ready-to-use
Validated for use with the VENTANA PD-L1 (SP263) assay and Roche uPath enterprise software.
Quick and automated
Pathologist-trained image analysis algorithm quickly calculates PD-L1 tumor cell positivity.
Accurate, consistent and confident
Actionable assessment of slide images that are objective and reproducible.
Enhancing your pathology workflow
- Enhanced accuracy with a Pathologist-trained image analysis algorithm which results in objective and reproducible scoring of slide images scanned on VENTANA DP 200 or VENTANA DP 600 slide scanner and stained with the VENTANA PD-L1 (SP263) Assay
- Fully embedded into the Roche uPath enterprise software to enable seamless viewing, aligning, syncing, sharing, and reporting
- Speed up time to results for user-defined regions of interest with whole slide analysis (WSA) and automated pre-computing of the slide image prior to pathologist assessment
- Quickly calculate PD-L1 tumor cell positivity
- A clear visual overlay highlights tumor cells with and without membranous staining for easy reference
Registration Status
*CE-IVD marked. For Research Use Only in the US. Not for use in diagnostic procedures in the US.
Refer to the product-specific labeling for the regulatory status of the scanner and uPath. When Research Use Only products are used with IVD products, the integrated workflow will be for Research Use Only and cannot be used for diagnostic procedures.
